Profound symptomatic bradycardia associated with combined mibefradil and beta-blocker therapy.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 9830391.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We report two cases where the addition of mibefradil to long term beta-blocker therapy in managing hypertension produced profound symptomatic bradycardia requiring cardiac pacing. Reports of a number of interactions between mibefradil and other cardioactive drugs have now led to its withdrawal from the market worldwide.